Novo Nordisk and San Francisco-based Sempre Health have announced their collaboration on a pilot program that will offer diabetes medications through the latter company’s monetary incentive and SMS-driven prescription refill platform. The partnership is hoping to engage 10,000 diabetes patients on Sempre’s platform within 2018.

from MobiHealthNews https://ift.tt/2qNYFjt

Related Posts:

0 comments:

Post a Comment

Popular Posts